Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): A compound of formula (I) or a pharmaceutically acceptable salt thereof:

$$(R^{2})_{n}$$

$$(R^{2})_{n}$$

$$(I)$$

wherein:

 R^1 represents a group of formula $-NR^aR^b$ or a nitrogen containing heterocyclyl group optionally substituted by one or more (eg. 1 to 4) C_{1-6} alkyl groups;

X represents a bond, $-(CR^cR^d)$ -, $-(CR^cR^d)$ -(CR^eR^f)-, $-(CR^cR^d)$ -(CR^eR^f)-(CR^eR^f)-(CR^gR^h)-, or -heterocyclyl-, wherein said heterocyclyl group may be optionally substituted by one or more (eg. 1 to 4) C_{1-6} alkyl groups; such that when R^1 represents $-NR^aR^b$, X does not represent a bond nor $-(CR^cR^d)$ -;

 R^a , R^b , R^c , R^d , R^e , R^f , R^g and R^h independently represent hydrogen or C_{1-6} alkyl; R^2 represents halogen, cyano, -CF₃, -CF₃O, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl or a group -CONR⁵R⁶;

n represents 0 to 3;

R³ and R⁴ independently represent hydrogen, halogen, cyano, -CF₃, -CF₃O, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁵R⁶;

 R^5 and R^6 independently represent hydrogen or C_{1-6} alkyl or together with the N atom to which they are attached may be fused to form a 5- to 7- membered N-containing aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

International Application No. PCT/GB2005/001106 International Filing Date: 24 March 2005

A represents an –aryl, -heteroaryl, -aryl-aryl, -aryl-heteroaryl, -heteroaryl-aryl or – heteroaryl-heteroaryl group;

wherein said aryl and heteroaryl groups of A may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C_{1-6} alkoxy, aryl C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonyl, arylsulfonyloxy, arylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonamido C_{1-6} alkyl, C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido C_{1-6} alkyl, arylcarboxamido C_{1-6} alkyl, aroyl, aroyl C_{1-6} alkyl, aryl C_{1-6} alkanoyl, or a group $CONR^7R^8$ or $SO_2NR^7R^8$, wherein R^7 and R^8 independently represent hydrogen or C_{1-6} alkyl or R^7 and R^8 together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group.

or solvates thereof.

- 2. (Original): A compound of formula (I) as defined in claim 1, wherein A represents aryl optionally substituted by one or more halogen atoms or heteroaryl.
- 3. (Currently amended): A compound of formula (I) as defined in claim 1 or elaim 2, wherein R¹ represents NR^aR^b, wherein R^a and R^b are independently hydrogen or methyl; or a nitrogen containing heterocyclyl group selected from pyrrolidinyl, piperidinyl, morpholinyl, azabicyclo[2.2.2]oct-3-yl or azepinyl optionally substituted by methyl or isopropyl.
- 4. (Original): A compound of formula (I) as defined in claim 1 selected from: [2-(3-Phenylsulfonylquinoline-8-yloxy)ethyl]dimethylamine;
- $8-(\{[(2S)-1-Methyl-2-pyrrolidinyl]methyl\}oxy)-3-(phenylsulfonyl) quinoline;$
- 3-(Phenylsulfonyl)-8-{[(2S)-2-pyrrolidinylmethyl]oxy}quinoline;
- 3-(Phenylsulfonyl)-8-{[2-(1-pyrrolidinyl)ethyl]oxy} quinoline;
- 3-(Phenylsulfonyl)-8-[(3R)-3-pyrrolidinyloxy]quinoline;

Dimethyl(1-methyl-2-{[3-(phenylsulfonyl)-8-quinolinyl]oxy} propyl)amine;

- $3-(Phenylsulfonyl)-8-\{[(2R)-2-pyrrolidinylmethyl]oxy\}$ quinoline;
- 3-(Phenylsulfonyl)-8-{[2-(1-piperidinyl)ethyl]oxy}quinoline;
- 8-{[2-(4-Morpholinyl)ethyl]oxy}-3-(phenylsulfonyl)quinoline;
- 8-(1-Azabicyclo[2.2.2]oct-3-yloxy)-3-(phenylsulfonyl)quinoline;
- 3-(Phenylsulfonyl)-8-{[3-(1-piperidinyl)propyl]oxy}quinoline;
- 8-{[2-(Hexahydro-1H-azepin-1-yl)ethyl]oxy}-3-(phenylsulfonyl)quinoline;
- ((3S,4R)-4-{[3-(Phenylsulfonyl)-8-quinolinyl]oxy}tetrahydro-3-furanyl)amine;
- (3S,4R)-N,N-Dimethyl-4-{[3-(phenylsulfonyl)-8-quinolinyl]oxy}tetrahydro-3-furanamine;
- 3-(Phenylsulfonyl)-8-(3-piperidinyloxy)quinoline;
- 3-(Phenylsulfonyl)-8-(4-piperidinyloxy)quinoline;
- 8-{[(3R)-1-Methyl-3-pyrrolidinyl]oxy}-3-(phenylsulfonyl)quinoline;
- 8-{[(3S)-1-Methyl-3-pyrrolidinyl]oxy}-3-(phenylsulfonyl)quinoline;
- 8-[(3R)-1-Azabicyclo[2.2.2]oct-3-yloxy]-3-(phenylsulfonyl)quinoline;
- 3-(Phenylsulfonyl)-8-[(3S)-3-pyrrolidinyloxy]quinoline;
- 8-[(1-Methyl-4-piperidinyl)oxy]-3-(phenylsulfonyl)quinoline;
- 8-[(1-Azabicyclo[2.2.2]oct-2-ylmethyl)oxy]-3-(phenylsulfonyl)quinoline;
- 8-[(1-Methyl-3-piperidinyl)oxy]-3-(phenylsulfonyl)quinoline;
- 8-[(3-Morpholinylmethyl)oxy]-3-(phenylsulfonyl)quinoline;
- 8-({[(2S)-1-(1-Methylethyl)-2-pyrrolidinyl]methyl}oxy)-3-(phenylsulfonyl)quinoline;
- N,N-Dimethyl-2-{[3-(phenylsulfonyl)-8-quinolinyl]oxy}-1-propanamine; or
- $5- Chloro-3- (phenylsulfonyl)-8-\{[2-(1-pyrrolidinyl)ethyl]oxy\} quinoline;$
- or a pharmaceutically acceptable salt thereof.
- 5. (Original): A compound of claim 4 wherein the salt is the hydrochloride salt.
- 6. (Currently amended): A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt as defined in <u>claim 1</u> any one of <u>claims 1 to 5</u> and a pharmaceutically acceptable carrier or excipient.

International Application No. PCT/GB2005/001106 International Filing Date: 24 March 2005

7. (Currently amended): A compound or pharmaceutically acceptable salt as defined in <u>claim 1</u> any one of claims 1 to 5 for use in the treatment of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.

8. (Cancelled).

- 9. (Currently amended): A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 any one of claims 1 to 5 for use in the treatment of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.
- 10. (Currently amended): A method of treating depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1. any one of claims 1 to 5.